| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 640 | 1.701 | 1.929 | 2.092 | 586 | 495 | 0 | 524 | 1.707 | 0 |
| Total Income - EUR | 640 | 1.701 | 1.929 | 2.092 | 586 | 495 | 0 | 524 | 2.311 | 0 |
| Total Expenses - EUR | 614 | 1.603 | 1.788 | 1.723 | 217 | 420 | 0 | 84 | 2.195 | 0 |
| Gross Profit/Loss - EUR | 27 | 98 | 141 | 369 | 369 | 75 | 0 | 440 | 115 | 0 |
| Net Profit/Loss - EUR | 7 | 47 | 83 | 306 | 351 | 60 | 0 | 425 | 97 | 0 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Galdocrin Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 801 | 783 | 786 | 0 | 0 |
| Current Assets | 6.655 | 4.884 | 4.063 | 3.484 | 3.478 | 3.120 | 3.063 | 3.107 | 1.983 | 1.926 |
| Inventories | 6.076 | 4.638 | 3.689 | 3.121 | 3.061 | 3.003 | 2.957 | 2.967 | 1.832 | 1.821 |
| Receivables | 115 | 114 | 112 | 110 | 107 | 105 | 103 | 103 | 100 | 100 |
| Cash | 465 | 133 | 262 | 253 | 310 | 12 | 2 | 37 | 51 | 5 |
| Shareholders Funds | -8.497 | -8.363 | -8.138 | -7.682 | -7.182 | -6.986 | -6.831 | -6.428 | -6.311 | -6.276 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 15.152 | 13.247 | 12.201 | 11.166 | 10.660 | 10.907 | 10.677 | 10.320 | 8.294 | 8.202 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4711 - 4711" | |||||||||
| CAEN Financial Year |
4711
|
|||||||||
Comments - Galdocrin Srl